Results 271 to 280 of about 47,580 (341)

Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study

HemaSphere, Volume 10, Issue 1, January 2026.
ABSTRACT Novel therapies are needed for patients with multiple myeloma (MM) and extramedullary plasmacytomas. The prospective, Phase II EMN19 study assessed the efficacy and safety of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (DaraVCD) in 40 patients with newly diagnosed MM (NDMM; n = 29) or at first relapse (RMM; n = 11) and ...
Meral Beksac, Tulin Fıratlı Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H. J. van der Velden, Berna H. Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz Seval, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Peter Sonneveld, Elena Zamagni, Evangelos Terpos   +18 more
wiley   +1 more source

Bispecific antibody targeting shared indel-derived neoantigen of APC. [PDF]

Front Immunol
Effenberger C, Wu X, Zhao P, Matsumoto S, Nakamura Y, Kiyotani K.   +5 more
europepmc   +1 more source

889 Comprehensive characterization of RNDO-564, a first-in-class CD28 x Nectin-4 bispecific antibody for the treatment of solid tumors [PDF]

Manpreet Kaur, Katja Rger, Soumili Chattopadhyay, Elaine C Chen, Ruth Chu, Starlynn Clarke, Laura Davison, Lynnae Jackson, Jacqueline Morgan, Udaya S. Rangaswamy, Ian E. Smith, Thomas Manley, Katherine E. Harris, Shelley Force Aldred, Nathan D. Trinklein   +14 more
openalex   +1 more source

Triplet regimens for frontline treatment of CLL—Great company or just a crowd?

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Standard frontline treatment of chronic lymphocytic leukemia (CLL) is with fixed‐duration venetoclax‐based doublets or indefinite covalent Bruton tyrosine kinase inhibitor (BTKI). Although these approaches achieve excellent results, venetoclax doublets have diminished efficacy in high‐risk biological subgroups, and indefinite covalent Bruton ...
Sean McKeague, John F. Seymour
wiley   +1 more source

Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma. [PDF]

Front Oncol
Akiyama H, Kakiuchi S, Sakamoto A, Tomigaki N, Fujioka S, Harima I, Niwa R, Takagi I, Kozuki Y, Miyata Y, Yoshihara K, Yoshihara S, Iwata N.   +12 more
europepmc   +1 more source

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

, 2016
Damian J. Green, Shani L. Frayo, Yukang Lin, Donald K. Hamlin, Darrell R. Fisher, Sofia H.L. Frost, Aimee L. Kenoyer, Mark D. Hylarides, Ajay K. Gopal, Theodore A. Gooley, Johnnie J. Orozco, Brian G. Till, Shyril O’Steen, Kelly Davis Orcutt, D. Scott Wilbur, K. Dane Wittrup, Oliver W. Press   +16 more
openalex   +1 more source

CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells. [PDF]

Sci Rep
Pape LJ, Gebhardt AJ, Dannenberg M, Risch H, Duttmann A, Weisel K, Hambach J, Koch-Nolte F, Bannas P.   +8 more
europepmc   +1 more source

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The optimal second‐line chemotherapy regimen for relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) remains uncertain. We retrospectively compared efficacy and safety between gemcitabine, carboplatin, dexamethasone, and rituximab (GCD‐R) and cyclophosphamide, high‐dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER ...
Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Naoki Hayase, Eri Takada, Takuro Matsumoto, Yuhei Shibata, Hiroshi Nakamura, Kei Fujita, Shin Lee, Tetsuji Morishita, Nobuhiro Kanemura, Senji Kasahara, Hideko Goto, Kenji Fukuno, Takeshi Hara, Michio Sawada, Hisashi Tsurumi, Masahito Shimizu   +18 more
wiley   +1 more source

Structure-guided bispecific antibody engineering confers broad protection against KP.3.1.1 and sarbecoviruses. [PDF]

iScience
Ma Y, Liu Q, Rehati P, Zhang Z, Wang Y, Liu Z, Chen J, Bai X, Hao A, Wang Y, Wen Y, Chen Z, Lu L, Zhao J, Wu F, Sun L, Huang J.   +16 more
europepmc   +1 more source

TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The combination of tafasitamab and lenalidomide (tafa‐lena) has demonstrated efficacy in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL), as evidenced by the L‐MIND study. To investigate the therapeutic potential and safety profile of tafa‐lena in real‐life, we conducted a national multicentric retrospective study.
Lisa Argnani, Cinzia Pellegrini, Ombretta Annibali, Piera Angelillo, Enrico Amaducci, Filippo Ballerini, Flaminia Bellisario, Andrea Bernardelli, Riccardo Bruna, Catello Califano, Giusy Cetani, Giulia Daghia, Enrico Derenzini, Antonio Frolli, Francesco Gaudio, Valerio Guarente, Ausilia Gorgone, Liardo Eliana Valentina, Elisa Lucchini, Dario Marino, Luca Nassi, Paolo Nicoli, Mattia Novo, Francesca Palombi, Caterina Patti, Vincenzo Pavone, Marcello Riva, Filomena Russo, Greta Scapinello, Alessandro Severino, Monica Tani, Daniele Vallisa, Beatrice Casadei, Alessandro Broccoli, Pier Luigi Zinzani   +34 more
wiley   +1 more source